In yesterday’s Wall Street session, Phio Pharmaceuticals Corp. (NASDAQ:PHIO) shares traded at $0.49, up 2.62% from the previous session.
PHIO stock price is now -18.46% away from the 50-day moving average and -35.87% away from the 200-day moving average. The market capitalization of the company currently stands at $7.60M.
With the price target of $4, H.C. Wainwright recently initiated with Buy rating for Phio Pharmaceuticals Corp. (NASDAQ: PHIO). .
Insiders disposed of 12,965 shares of company stock worth roughly $6352.849999999999 over the past 1 year. A total of 0.60% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in PHIO stock. A new stake in Phio Pharmaceuticals Corp. shares was purchased by HRT FINANCIAL LP during the first quarter worth $9,000. ERGOTELES LLC invested $6,000 in shares of PHIO during the first quarter. In total, there are 12 active investors with 5.70% ownership of the company’s stock.
On Monday morning Phio Pharmaceuticals Corp. (NASDAQ: PHIO) stock kicked off with the opening price of $0.5100. During the past 12 months, Phio Pharmaceuticals Corp. has had a low of $0.47 and a high of $2.42. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 7.00, and a quick ratio of 7.00. The fifty day moving average price for PHIO is $0.6044 and a two-hundred day moving average price translates $0.7684 for the stock.
The latest earnings results from Phio Pharmaceuticals Corp. (NASDAQ: PHIO) was released for Jun, 2022. For the current quarter, analysts expect PHIO to generate $12.5M in revenue.
Phio Pharmaceuticals Corp.(PHIO) Company Profile
Phio Pharmaceuticals Corp. develops immuno-oncology therapeutics in the United States. It offers INTASYL therapeutic platform focuses on targeting tumor and immune cells by regulating genes of the immune system. The company develops PH-762 that activates immune cells to recognize and kill cancer cells by reducing the expression of the checkpoint protein PD-1 for immunotherapy in adoptive cell transfer (ACT); PH-894 that silences the epigenetic protein BRD4, which is an intracellular regulator of gene expression for use in ACT; and PH-804 that targets the suppressive immune receptor TIGIT, which is a checkpoint protein present on T cells and natural killer cells for use in ACT. It has collaborations with AgonOx Inc. on clinical development of novel T cell-based cancer immunotherapies. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.